Introduction
============

Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive movements, abnormal posturing, or both. Dystonia comprises a heterogeneous patient population due to a broad spectrum of underlying acquired and inherited etiologies \[[@B1]\].

Over the past decades, deep brain stimulation of the globus pallidus internus (GPi-DBS) has emerged as a safe treatment option with a good response in non-lesional, mostly isolated forms of dystonia and a more variable response in combined forms of dystonia that are due to a static lesion or neurodegenerative process \[[@B2]\]. The application of this elective neurosurgical procedure therefore frequently gives rise to discussion, especially in secondary dystonia patients.

The effect of GPi-DBS has been predominantly measured with objective standardized dystonia rating scales \[[@B2]\]. However, the variability of dystonic symptoms within days, or even hours or minutes, makes it difficult to reliably capture overall dystonia severity in just one evaluation. Furthermore, it is unclear how dystonia severity reflects disease burden and there is only weak evidence that a reduction in symptoms in isolated forms of dystonia may correlate with meaningful improvements in functioning \[[@B3][@B4]\].

In line with the World Health Organization guidelines advocating patient-centered outcome measures \[[@B5]\], we aimed to systematically evaluate the effect of DBS in terms of individualized functional priorities set by the patient and/or their caregivers.

Methods
=======

Patients
--------

We prospectively included fifteen consecutive dystonia patients that received GPi-DBS between January 2013 and July 2016. All patients were evaluated pre and 1-year post-operatively screened by a multidisciplinary team. The local ethical committee classified the study as care as usual.

Outcome measures
----------------

Priorities were identified by the Canadian Occupational Performance Measure (COPM). The COPM is an individualized outcome measure to capture everyday problems that impact daily functioning. Together with a trained occupational therapist, patients and/or caregivers imaginary walked through a typical day in the patient's life to identify priorities that they would like to see improved by GPi-DBS. For the three most important priorities performance (1--10) and satisfaction (1--10) were rated. Change between pre- and postoperative ratings was used for further analyses. At the 1-year follow-up, patients and/or their caregivers were blinded for their pre-operative ratings. A difference of two or more points was considered clinically significant \[[@B6]\].

Dystonia severity was assessed with the motor subscale of the Burke-Fahn-Marsden dystonia rating scale (BFMDRS). Videos were blinded for operative status and rated by experienced clinicians (ALB, RB, KJP, MFC) who were blinded to treatment state. Mean total scores were calculated. In order to be able to compare the results in all patients (generalized and focal/segmental) the relative change in BFMDRS (% of improvement) was used for further analyses. In addition, patients were subdivided into motor 'responders' (\>20% change in BFMDRS score) and 'non-responders' (\<20% change in BFMDRS score) \[[@B7]\]. For absolute scores, see supplementary Table [1](#ST1){ref-type="table"}.

Data-analysis
-------------

Data-analysis was performed using Statistical Package for the Social Sciences (SPSS, version 23.0). Due to the heterogeneity of the sample, medians and interquartile ranges (IQR) were used. Differences between pre- and postoperative scores were compared with the Wilcoxon Signed Ranked Test for total group and the responders and non-responder subgroups. Correlations between the outcome measures were calculated with the Spearman's ρ.

Results
=======

Baseline characteristics, etiology and pharmacological treatment of all 15 patients (8 male; median age 32y range 8--65; median disease duration 8y range 3--47) are shown in Table [1](#T1){ref-type="table"}.

###### 

Patient characteristics and pharmacological treatment.

  ---- ----------------- ------------------- ------------------------- ------------------------ ------------------------------------------------------------------------------ ----------------------------------------------------
  Pt   Gender/age (yr)   Body distribution   Isolated or combined      Etiology                 Pre-operative medical treatment                                                Post-operative medical treatment
                                                                                                                                                                               
  1    M/8               Generalized         Combined (spasticity)     Mitochondrial disorder   Gabapentin 100 mg; intrathecal baclofen 3 ug/hr                                Unchanged
  2    M/8               Generalized         Isolated                  Idiopathic               THP 20 mg                                                                      No
  3    M/18              Segmental           Isolated                  Idiopathic               THP 24 mg; BTX                                                                 THP 24 mg
  4    F/22              Generalized         Isolated                  ACTB mutation            THP 16 mg; tramadol 50 mg                                                      THP 12 mg; clonazepam 1.5 mg; clozapine 18.75; BTX
  5    F/32              Segmental           Isolated                  Idiopathic               Ibuprofen; BTX                                                                 No
  6    M/9               Generalized         Isolated                  DYT-THAP1                THP 21 mg; baclofen 12.5 mg                                                    THP 11 mg
  7    M/22              Segmental           Isolated                  TTPA                     Vitamin E                                                                      Unchanged
  8    M/47              Generalized         Combined (spasticity)     Cerebral palsy           Antidepressants                                                                Unchanged
  9    M/53              Segmental           Isolated                  Idiopathic               Clonazepam 0.5 mg; BTX                                                         BTX
  10   F/65              Segmental           Combined (parkinsonism)   Idiopathic               Pramipexole; L-dopa; Diazepam 5 mg; BTX                                        Pramipexole; L-Dopa
  11   F/48              Generalized         Isolated                  ACTB mutation            THP 12 mg; clozapine 12.5 mg; oxazepam 10 mg; diclofenac; BTX antidepressant   THP 12 mg; clozapine 12.5 mg; antidepressant
  12   F/63              Segmental           Isolated                  Idiopathic               Clonazepam 2.5 mg                                                              Clonazepam 0.5 mg
  13   M/62              Segmental           Isolated                  Idiopathic               BTX                                                                            Clonazepam 1.0 mg; BTX
  14   F/8               Generalized         Combined (spasticity)     Cerebral palsy           THP 1.5 mg; baclofen 12 mg; gabapentin 600 mg; clonazepam 0.5 mg               Unchanged
  15   F/63              Segmental           Isolated                  Idiopathic               No                                                                             No
  ---- ----------------- ------------------- ------------------------- ------------------------ ------------------------------------------------------------------------------ ----------------------------------------------------

ACTB: beta-actin gene; BTX: botulinum toxin injections; THP: trihexiphenidyl; TTPA α-tocopherol transfer protein -- vitamin E.

Individual priorities
---------------------

The 45 priorities (3 per patient) were categorized in self-care/activities of daily living (ADL) (n = 10); comfort in sitting and sleep (n = 9); communication (n = 7); social/leisure activities (n = 7); and mobility (n = 12). Communication priorities involved the ability to use an electric communication device, sign language or normal social interaction without interference of dystonic posturing. Social activities included sports, interactive games or going out for dinner. Mobility comprised walking, cycling, driving a car or the use of public transport.

For each patient, priorities comprised at least two categories. There was a very strong correlation between performance and satisfaction scores (ρ = 0.86, p \< 0.0001) and both scores significantly improved after the application of DBS (Table [2](#T2){ref-type="table"}). At patient level, a clinically significant change in satisfaction in two or three individual priorities was reported in 73% (11) of the patients. In 47% all three priorities were improved, in 27% two priorities were improved, in 13% one priority was improved and in 13% none of the priorities was improved.

###### 

Pre- and postoperative COPM scores for all functional priorities and per subcategory.

  ------------------- ------------------ ---------------------- ---------- ---------------- ---------------------- ---------
                      COPM-Performance   COPM-Satisfaction                                                         
                                                                                                                   
  Baseline            1 year             Improved priorities†   Baseline   1 year           Improved priorities†   
                                                                                                                   
  All priorities      3.0 (1.0--4.0)     7.0 (5.0--8.0)         32/45\*    2.0 (1.0--3.5)   7.0 (4.0--8.5)         31/45\*
  Sitting and sleep   3.0 (2.0--4.0)     7.0 (5.5--8.0)         8/9        2.0 (1.5--3.5)   7.0 (3.5--9.0)         5/9
  Self-care/ADL       1.5 (1.0--4.3)     6.0 (2.5--7.3)         6/10       1.5 (1.0--3.0)   6.5 (2.5--7.3)         7/10
  Communication       4.0 (3.0--4.0)     8.0 (6.0--10.0)        5/7        3.0 (1.0--4.0)   9.0 (7.0--9.0)         6/7
  Social/leisure      3.0 (1.0--4.0)     7.0 (3.0--7.0)         4/7        3.0 (1.0--4.0)   6.0 (1.0--7.0)         4/7
  Transfer            2.5 (1.3--4.8)     6.5 (5.3--7.0)         9/12       2.0 (1.0--3.8)   6.5 (5.3--8.8)         9/12
  ------------------- ------------------ ---------------------- ---------- ---------------- ---------------------- ---------

ADL activities of daily living; † Change or 2 point or more between baseline and 1-year post-operative score. \* p \< 0.0001.

Dystonia severity
-----------------

BFMDRS scores improved with a median change of 30% (pre 46.8 IQR 17.0--66.0 vs post 35.4 IQR 11.3--53.0; p = 0.027). For absolute changes, see supplementary table [1](#ST1){ref-type="table"}. Eight patients (53%) were classified as responders with a decrease in their BFMDRS of more than 20% and seven (47%) as non-responders.

The non-responders were two patients with cerebral palsy (case 8 and 14), one patient with a mitochondrial disorder (case 1), one patient with DYT-THAP1 (case 6) and three patients with segmental dystonia (case 3, 12 and 15).

Priorities versus dystonia severity
-----------------------------------

Change in dystonia severity did neither correlate with change in performance (ρ = --0.15, p = 0.601) nor satisfaction score (ρ = 0.17, p = 0.557).

Seven of the eight responders reported a clinically significant improvement in performance and satisfaction on at least two or three individual functional priorities. In the group of non-responders, despite the lower motor response, clinical significant improvement in at least two priorities was achieved in four of these patients for performance and three for satisfaction, with a statistically significant change in COPM score (Case 6, 12, 14 and 15, p = 0.017).

Discussion
==========

This prospective case series aimed to systematically evaluate the effectiveness of GPi-DBS as measured with change in preoperatively set functional priorities. The priorities of the patients and their caregivers lay within the domains of ADL, seating and sleep, communication, social/leisure activities and mobility. A clinically significant motor response coincided with improvements in functional priorities in 7/8 patients. Interestingly, half of the motor 'non-responder' patients also showed a clinically significant change in two or three priorities. Our findings are in line with a previous study in childhood dystonia showing that DBS may lead to improvement of functional goals also in patients with only moderate to 'insignificant' motor response \[[@B8]\].

In contrast to the vast majority of efficacy studies primarily focusing on motor response, we evaluated effect of GPi-DBS by looking at functional priorities. These priorities provide an unique insight in what patients and their caregivers identify as most important aspects in daily living. Given the heterogeneous nature of dystonia, it is not surprising that needs varied greatly between patients. An additional advantage is that this method may facilitate recognition of patients that might be unsuitable for the procedure due to goals that are unrealistic or not likely to be achieved by GPi-DBS. One might argue that with a goal-oriented approach changes are subjective to the patients' perception of improvement rather than objective symptom reduction. In addition, a potential placebo effect cannot be excluded in the absence of a control group. However, we agree with Kubu and colleagues that the main goal of DBS is to improve quality of life as perceived by the patient more than by the clinician, and that the effect of an elective neurosurgical option as DBS should be measured accordingly \[[@B9]\]. In the future, it would be useful to objectify the patient centered outcome. This can be done by transforming the patients' priorities into a treatment goal and pre-operatively decide with the patient and caregivers when the goal is met, for instance by using the goal attainment scale.

The heterogeneous patient sample may be seen as a limitation, both in terms of age as well as etiology. On the other hand, it can be seen as an advantage for the generalizability of the study. We did not correct for changes in medication, which could account for some of the perceived improvements. We realize that our conclusions are bases on a small case series with a possibly limited power, but hope these results serve as a pilot study to trigger future studies focusing on the effectiveness of GPi-DBS in dystonia. First to assess to what extent a good motor outcome corresponds with the perceived outcome on the patient's priorities. This may not always be the case, as 1/8 motor responders did not reach a significant improvement on his priorities, and might provide clarity in the repeatedly reported discrepancy between motor outcome and patient reported outcome. A systematical use of patient centered outcomes might shine a new light on the current opinion that GPi-DBS is more effective in isolated than in combined forms of dystonia.

In conclusion, the effect of GPi-DBS should be measured not by motor symptom reduction alone, as clinically significant improvements on individual predefined priorities can be achieved irrespective of motor response. In addition, a goal- or patient-oriented approach provides unique insights in the priorities in daily living of dystonia patients and their caregivers. This may not only be of added value for DBS candidates, but also for patients across the entire dystonia population.

###### 

Absolute Burke-Fahn-Marsden Dystonia Rating Scale score pre- and postoperatively (n = 15).

  --------- ----------------- -------------- ---------------------- ----------------- -----
  Pt        Gender/age (yr)   Distribution   Isolated or combined   Mean BFMDRS-M\*   
                                                                                      
  Pre-DBS   Post-DBS                                                                  
                                                                                      
  1         M/8               Generalized    Combined               66                70
  2         M/8               Generalized    Isolated               55                31
  3         M/18              Segmental      Isolated               47                44
  4         F/22              Generalized    Isolated               81                33
  5         F/32              Segmental      Isolated               33                13
  6         M/9               Generalized    Isolated               71                69
  7         M/22              Segmental      Isolated               14                5
  8         M/47              Generalized    Combined               49                53
  9         M/53              Segmental      Isolated               23                14
  10        F/65              Segmental      Combined               16                8
  11        F/48              Generalized    Isolated               64                45
  12        F/63              Segmental      Isolated               17                18
  13        M/62              Segmental      Isolated               20                11
  14        F/8               Generalized    Combined               102               107
  15        F/63              Segmental      Isolated               9                 10
  --------- ----------------- -------------- ---------------------- ----------------- -----

\* Mean BFMDRS-M was calculated from the two scores of the experts.

BFMDRS-M: Burke-Fahn-Marsden Dystonia Rating Scale, Motor subcale; DBS: Deep brain stimulation.
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